Next Article in Journal
Similarity and Differences in Inflammation-Related Characteristics of the Peripheral Immune System of Patients with Parkinson’s and Alzheimer’s Diseases
Previous Article in Journal
Diphlorethohydroxycarmalol from Ishige okamurae Suppresses Osteoclast Differentiation by Downregulating the NF-κB Signaling Pathway
Previous Article in Special Issue
Immunotherapy for Prostate Cancer: Where We Are Headed

Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy

Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2017, 18(12), 2642;
Received: 20 November 2017 / Revised: 3 December 2017 / Accepted: 5 December 2017 / Published: 6 December 2017
(This article belongs to the Special Issue Targeting Immune Checkpoints and Immunotherapy)
Cancer immunotherapy has been a great breakthrough, with immune checkpoint inhibitors leading the way. Despite the clinical effectiveness of certain immune checkpoint inhibitors, the overall response rate remains low, and the effectiveness of immunotherapies for many tumors has been disappointing. There is substantial interest in looking for additional immune checkpoint molecules that may act as therapeutic targets for cancer. Recent advances during the last decade have identified several novel immune checkpoint targets, including lymphocyte activation gene-3 (LAG-3), B and T lymphocyte attenuator (BTLA), programmed death-1 homolog (PD-1H), T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIM-3)/carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1), and the poliovirus receptor (PVR)-like receptors. The investigations into these molecules have generated promising results in preclinical studies. Herein, we will summarize our current progress and understanding of these newly-characterized immune checkpoints and their potential application in cancer immunotherapy. View Full-Text
Keywords: immunotherapy; cosignaling; immune checkpoints immunotherapy; cosignaling; immune checkpoints
Show Figures

Figure 1

MDPI and ACS Style

Torphy, R.J.; Schulick, R.D.; Zhu, Y. Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy. Int. J. Mol. Sci. 2017, 18, 2642.

AMA Style

Torphy RJ, Schulick RD, Zhu Y. Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy. International Journal of Molecular Sciences. 2017; 18(12):2642.

Chicago/Turabian Style

Torphy, Robert J., Richard D. Schulick, and Yuwen Zhu. 2017. "Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy" International Journal of Molecular Sciences 18, no. 12: 2642.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop